Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15897060 | 0.73 | CYP19A1 (0.54) | CYP19A1HPGDKMT2ASMN1; SMN2MAPT | |
| SCHEMBL16701076 | 0.73 | CYP19A1 (0.70) | CYP19A1LMNATSHRMAPK1HPGD | |
| SCHEMBL17225764 | 0.72 | CYP19A1 (0.55) | CYP19A1TP53ALOX12MAPK1PDE4A | |
| SCHEMBL15815752 | 0.71 | CYP19A1 (0.48) | CYP19A1TP53ALOX12LMNATSHR | |
| SCHEMBL1412553 | 0.67 | TP53 (0.56) | CYP19A1TP53ALOX12TSHRMAPK1 | |
| SCHEMBL20143010 | 0.67 | TP53 (0.56) | CYP19A1TP53ALOX12LMNATSHR | |
| SCHEMBL23153541 | 0.67 | CYP19A1 (0.44) | CYP19A1TP53ALOX12LMNATSHR | |
| SCHEMBL28916904 | 0.67 | SLC5A1 (0.44) | CYP19A1TP53ALOX12LMNATSHR | |
| SCHEMBL23234141 | 0.66 | TP53 (0.51) | CYP19A1TP53ALOX12LMNAMAPK1 | |
| SCHEMBL14511339 | 0.66 | TSHR (0.49) | CYP19A1TP53ALOX12LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688161-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20240336608-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-10-10 | — | — | US | disclosed |
| WO-2024206357-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336608-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL1RN | CYP19A1 1455/4885TP53 2506/4885ALOX12 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.